膽囊、膽道癌

AbGn-107

臨床試驗

治療藥物

AbGn-107

疾病人口數

膽囊、膽道癌的患者約佔胃腸道腫瘤的3%、佔所有肝膽惡性腫瘤的10-15%[1]。
在美國，每年診斷出約20,000例肝和膽道癌的新病例。膽道癌是繼肝細胞癌後第二常見的原發性肝膽癌，每年診斷出大約7,500例新病例；其中約有5,000例是膽囊癌，約2,000-3,000例是膽管癌[2]。
試驗說明
評估AbGn-107的安全性, 最大耐受劑量 (MTD) 和初步針對膽囊、膽道癌療效。
試驗醫學中心
Phoenix, AZ Mayo Clinic
  • Phoenix, Arizona, United States, 85054
  • Justin Weber
  • 480-342-6029
  • Weber.Justin@mayo.edu
San Francisco, CA University of California
  • San Francisco, California, United States, 94143
  • Pranay Chaurasia
  • 415-353-8449
  • Pranay.Chaurasia@ucsf.edu
Boston, MA Massachusetts General Hospital
  • Boston, Massachusetts, United States, 02114
  • Amy Gisondi
  • AGISONDI@mgh.harvard.edu
Boston, MA Beth-Israel Deaconess Medical Center
  • Boston, Massachusetts, United States, 02215
  • Justin Sun
  • 617-975-7463
  • jsun7@bidmc.harvard.edu
Boston, MA Dana-Farber Cancer Institute
  • Boston, Massachusetts, United States, 02215
  • Alexandra Bird
  • 617-632-5575
  • Alexandra_Bird@DFCI.HARVARD.EDU
Seattle, WA United States, Washington University of Washington, Seattle Cancer Care Alliance
  • Seattle, Washington, United States, 98109
  • Camille Biggins
  • 206-606-1646
  • cbiggins@seattlecca.org
Taichung, TW China Medical University Hospital
  • Taichung, Taiwan, 404
  • Yu-Ting Ho
  • 04-22052121 ext 5057
  • blessyou1982@gmail.com
Tainan, TW National Cheng Kung University Hospital
  • Tainan, Taiwan, 48
  • Ray-Fan Su
  • 0910-876172
  • srf106@gmail.com
Taipei, TW National Taiwan University Hospital
  • Taipei, Taiwan, 100
文獻引用
1. Bile duct cancer. NIH. Available at
2. Pancreatic & Biliary Cancer. NIH. Available at
更多關於我們的臨床試驗訊息，請上ClinicalTrials.gov查詢